Doug Russell: “I was not going to let the cancer beat me.”
“I was not going to let the cancer beat me.”
The first piece of news was ominous: Doug Russell had stage 4 melanoma.
The second was worse: The cancer had spread to his lungs.
“Like everyone who is first diagnosed, I was devastated,” says the building supply company executive from Duluth, Ga. “But I quickly learned that you’ve got to move past the negative feelings and get into the ready-to-fight stage.”
At first, the fight didn’t go so well; standard treatments yielded poor results.
So Doug’s physician, Dr. David Lawson at Emory’s Winship Cancer Institute in Atlanta, recommended an aggressive series of Interleukin-2 treatments – a therapy that was only available through a clinical trial.
“I wasn’t very familiar with clinical trials,” Doug said, “but I wanted to do anything I could to get better. Plus, having the opportunity to help other people was a strong incentive. I knew that my participation meant I might help save other lives.”
Five years after his first diagnosis, Doug was cancer free. He credits the IL-2 treatments from the clinical trial for his recovery as well as his keeping a positive outlook throughout therapy.
“I didn’t want to know what the side effects might be because I didn’t want to focus on them,” he says. “I went into every protocol just knowing that it would work.”
Back to Survivors' Voices
Cancer Survivorship Connection
Cancer patients and survivors should not get COVID-19. A three-time cancer survivor should definitely not get COVID. But I did. And it was not good. Here is my story and the lessons I learned that might be of value to others.
Three women, three cancer survivorship journeys, three missions resulting in nonprofits started to help and support others fighting cancer.
Thanks to funding awarded by the Centers for Disease Control for five-years beginning July 2020, Georgia CORE and Augusta University are partners in the Georgia Colorectal Cancer Control Program, which is increasing CRC screenings in southeast and southwest Georgia.